GB201204696D0 - Therapy - Google Patents

Therapy

Info

Publication number
GB201204696D0
GB201204696D0 GBGB1204696.7A GB201204696A GB201204696D0 GB 201204696 D0 GB201204696 D0 GB 201204696D0 GB 201204696 A GB201204696 A GB 201204696A GB 201204696 D0 GB201204696 D0 GB 201204696D0
Authority
GB
United Kingdom
Prior art keywords
diameter
less
macropores
therapy
diameter greater
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1204696.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
University of Brighton
Original Assignee
UCL Business Ltd
University of Brighton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd, University of Brighton filed Critical UCL Business Ltd
Priority to GBGB1204696.7A priority Critical patent/GB201204696D0/en
Publication of GB201204696D0 publication Critical patent/GB201204696D0/en
Priority to SG11201405771QA priority patent/SG11201405771QA/en
Priority to EP19211615.0A priority patent/EP3650031B1/en
Priority to KR1020207022420A priority patent/KR102441934B1/ko
Priority to US14/385,332 priority patent/US9844568B2/en
Priority to EP13711116.7A priority patent/EP2825181B1/en
Priority to NZ631429A priority patent/NZ631429A/en
Priority to DK13711116.7T priority patent/DK2825181T3/da
Priority to IN7637DEN2014 priority patent/IN2014DN07637A/en
Priority to MYPI2014002656A priority patent/MY169093A/en
Priority to AU2013234099A priority patent/AU2013234099B2/en
Priority to BR112014022810-8A priority patent/BR112014022810B1/pt
Priority to KR1020147029083A priority patent/KR102142504B1/ko
Priority to JP2014561519A priority patent/JP6293680B2/ja
Priority to PCT/GB2013/050673 priority patent/WO2013136094A1/en
Priority to EA201491690A priority patent/EA038965B1/ru
Priority to CN201380025257.6A priority patent/CN104363916B/zh
Priority to ZA2014/06989A priority patent/ZA201406989B/en
Priority to JP2018023609A priority patent/JP6647570B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/16—Pore diameter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
GBGB1204696.7A 2012-03-16 2012-03-16 Therapy Ceased GB201204696D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB1204696.7A GB201204696D0 (en) 2012-03-16 2012-03-16 Therapy
CN201380025257.6A CN104363916B (zh) 2012-03-16 2013-03-15 用于治疗或预防肝病的用途的多孔碳颗粒
IN7637DEN2014 IN2014DN07637A (enExample) 2012-03-16 2013-03-15
AU2013234099A AU2013234099B2 (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease
KR1020207022420A KR102441934B1 (ko) 2012-03-16 2013-03-15 간질환의 치료 또는 예방용 다공성 탄소 입자
US14/385,332 US9844568B2 (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease
EP13711116.7A EP2825181B1 (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease
NZ631429A NZ631429A (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease
DK13711116.7T DK2825181T3 (da) 2012-03-16 2013-03-15 Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom
SG11201405771QA SG11201405771QA (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease
MYPI2014002656A MY169093A (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease
EP19211615.0A EP3650031B1 (en) 2012-03-16 2013-03-15 POROUS CARBON PARTICLES INTENDED FOR USE IN THE TREATMENT OR PREVENTION OF LIVER DISEASE
BR112014022810-8A BR112014022810B1 (pt) 2012-03-16 2013-03-15 Partículas de carbono poroso para uso no tratamento ou prevenção de doença no fígado
KR1020147029083A KR102142504B1 (ko) 2012-03-16 2013-03-15 간질환의 치료 또는 예방용 다공성 탄소 입자
JP2014561519A JP6293680B2 (ja) 2012-03-16 2013-03-15 肝疾患の治療及び予防における使用のための多孔性炭素粒子
PCT/GB2013/050673 WO2013136094A1 (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease
EA201491690A EA038965B1 (ru) 2012-03-16 2013-03-15 Частицы пористого углерода для применения при лечении или профилактике заболевания печени
ZA2014/06989A ZA201406989B (en) 2012-03-16 2014-09-25 Porous carbon particles for use in the treatment or prevention of liver disease
JP2018023609A JP6647570B2 (ja) 2012-03-16 2018-02-14 肝疾患の治療及び予防における使用のための多孔性炭素粒子

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1204696.7A GB201204696D0 (en) 2012-03-16 2012-03-16 Therapy

Publications (1)

Publication Number Publication Date
GB201204696D0 true GB201204696D0 (en) 2012-05-02

Family

ID=46052080

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1204696.7A Ceased GB201204696D0 (en) 2012-03-16 2012-03-16 Therapy

Country Status (16)

Country Link
US (1) US9844568B2 (enExample)
EP (2) EP2825181B1 (enExample)
JP (2) JP6293680B2 (enExample)
KR (2) KR102441934B1 (enExample)
CN (1) CN104363916B (enExample)
AU (1) AU2013234099B2 (enExample)
BR (1) BR112014022810B1 (enExample)
DK (1) DK2825181T3 (enExample)
EA (1) EA038965B1 (enExample)
GB (1) GB201204696D0 (enExample)
IN (1) IN2014DN07637A (enExample)
MY (1) MY169093A (enExample)
NZ (1) NZ631429A (enExample)
SG (1) SG11201405771QA (enExample)
WO (1) WO2013136094A1 (enExample)
ZA (1) ZA201406989B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
ES2727153T3 (es) * 2014-04-17 2019-10-14 Immutrix Therapeutics Inc Composiciones de destoxificación terapéutica y métodos para la preparación y utilización de las mismas
TWI607765B (zh) * 2014-08-27 2017-12-11 Kureha Corp Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
EP3476818A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved carbon source
EP3476817A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved amphiphilic species
WO2019131209A1 (ja) * 2017-12-27 2019-07-04 株式会社クラレ 活性炭およびその製法
JP7228498B2 (ja) * 2018-10-24 2023-02-24 フタムラ化学株式会社 フェノール樹脂の製造方法
WO2020085282A1 (ja) * 2018-10-24 2020-04-30 フタムラ化学株式会社 フェノール樹脂の製造方法
JP7338993B2 (ja) * 2019-03-06 2023-09-05 株式会社クラレ 多孔質炭素および多孔質炭素の製造方法
JP7061640B2 (ja) * 2019-04-16 2022-04-28 フタムラ化学株式会社 活性炭吸着剤の製造方法
WO2020213559A1 (ja) * 2019-04-16 2020-10-22 フタムラ化学株式会社 活性炭吸着剤の製造方法
JP7563145B2 (ja) * 2019-12-05 2024-10-08 ａｒｔｉｅｎｃｅ株式会社 多孔質炭素及びその製造方法
WO2024261472A1 (en) * 2023-06-20 2024-12-26 Yaqrit Limited Porous carbon particles for use in therapy
KR102971111B1 (ko) 2023-09-05 2026-06-02 한국생산기술연구원 열경화성 에폭시 조성물, 이의 경화물 및 용도
CN121925310A (zh) * 2025-03-28 2026-04-24 大阪燃气化学有限公司 麻醉气体吸附剂、麻醉气体吸附过滤器、吸入麻醉系统以及麻醉气体的去除方法
JP7724390B1 (ja) * 2025-03-28 2025-08-15 大阪ガスケミカル株式会社 麻酔ガス吸着剤、麻酔ガス吸着剤の製造方法、麻酔ガス吸着フィルター、吸入麻酔システム、および、麻酔ガスの除去方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5332637B2 (enExample) * 1973-05-09 1978-09-09
JPS51151693A (en) 1975-06-23 1976-12-27 Eisai Co Ltd Coated bead-like activated carbon for blood purification
JPS5673542A (en) 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
JPS5731864A (en) * 1980-08-04 1982-02-20 Teijin Ltd Oral activated carbon microcapsule
RU2177319C2 (ru) * 1999-03-30 2001-12-27 Российская медицинская академия последипломного образования МЗ РФ Способ лечения гиперэндотоксинемии
GB0019417D0 (en) 2000-08-09 2000-09-27 Mat & Separations Tech Int Ltd Mesoporous carbons
JP3522708B2 (ja) 2001-04-11 2004-04-26 呉羽化学工業株式会社 経口投与用吸着剤
JP4311923B2 (ja) * 2002-10-07 2009-08-12 株式会社クレハ 経口投与用肝疾患治療又は予防剤
EP1407772B9 (en) 2002-10-09 2007-02-21 Kureha Corporation Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases
CA2504517C (en) 2002-11-01 2008-08-12 Kureha Corporation Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2005089306A (ja) * 2003-09-12 2005-04-07 Ajinomoto Co Inc 炎症性腸疾患治療用の経直腸投与製剤
JP4382629B2 (ja) * 2003-10-22 2009-12-16 株式会社クレハ 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤
KR101135260B1 (ko) * 2003-10-22 2012-04-12 가부시키가이샤 쿠레하 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제
TWI370013B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
TWI370012B (en) 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
JP2007045775A (ja) 2005-08-11 2007-02-22 Japan Organo Co Ltd 含水活性炭及びその製造方法
DE102005062160A1 (de) 2005-12-19 2007-06-21 BLüCHER GMBH Aktivkohle für die medizinische Verwendung
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
CA2660883C (en) 2006-10-09 2014-12-09 British American Tobacco (Investments) Limited Carbonising and/or activating carbonaceous material
BRPI0719161A2 (pt) 2006-10-09 2014-02-04 British American Tobacco Co Processos para produzir glóbulos sólidos discretos de material polimérico, para preparar um produto de carbono ativado, e para preparar um produto particulado carbonizado, aparelho para formar glóbulos sólidos discretos de material polimérico, métodos para carbonizar e ativar material carbonáceo, e para preparar carbono ativado, e, forno rotativo.
WO2010138519A2 (en) 2009-05-27 2010-12-02 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres for the treatment of pruritus
GB0921528D0 (en) * 2009-12-09 2010-01-27 Mast Carbon Internat Ltd Carbon and its use in blood cleansing applications
PL2538930T3 (pl) 2010-02-23 2016-11-30 Preparaty do doustnego dostarczania środków adsorbujących do jelita
JP5984352B2 (ja) * 2010-10-12 2016-09-06 フタムラ化学株式会社 経口投与用医薬用吸着剤の製造方法
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy

Also Published As

Publication number Publication date
KR102441934B1 (ko) 2022-09-08
DK2825181T3 (da) 2020-04-14
IN2014DN07637A (enExample) 2015-05-15
EP2825181A1 (en) 2015-01-21
EP3650031B1 (en) 2026-07-01
MY169093A (en) 2019-02-18
EP2825181B1 (en) 2020-01-08
EA201491690A1 (ru) 2015-02-27
JP6647570B2 (ja) 2020-02-14
NZ631429A (en) 2016-09-30
EA038965B1 (ru) 2021-11-16
AU2013234099B2 (en) 2017-03-30
SG11201405771QA (en) 2014-10-30
JP6293680B2 (ja) 2018-03-14
KR20200096991A (ko) 2020-08-14
KR102142504B1 (ko) 2020-08-07
BR112014022810B1 (pt) 2021-04-13
AU2013234099A1 (en) 2014-10-02
CN104363916B (zh) 2018-09-25
KR20150002675A (ko) 2015-01-07
WO2013136094A1 (en) 2013-09-19
CN104363916A (zh) 2015-02-18
ZA201406989B (en) 2015-12-23
EP3650031A1 (en) 2020-05-13
EP3650031C0 (en) 2026-07-01
US20150064256A1 (en) 2015-03-05
US9844568B2 (en) 2017-12-19
JP2015516373A (ja) 2015-06-11
JP2018111699A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
IN2014DN07637A (enExample)
EP4465371A3 (en) Electroactive materials for metal-ion batteries
TW200728201A (en) Precipitated silicas with particular pore size distribution
WO2013128402A3 (en) Porous inorganic body
WO2011091092A3 (en) Microporous activated carbon for edlcs
CY1124471T1 (el) Ένα πορωδες υλικο πυριτιας προς χρηση ως ενα φαρμακευτικο ή διαιτητικο ενεργο συστατικο
TN2016000238A1 (en) Tricyclic compounds as anticancer agents.
TW200722374A (en) Precipitated silicas with a particular pore size distribution
PH12015501370A1 (en) Compounds and methods for kinase modulation, and indications therefor
IN2014DN07384A (enExample)
MX2012001590A (es) Compuesto poroso permeable.
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
WO2014169078A3 (en) 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2013112643A8 (en) Low density, highly porous nano structure
EP3044168A4 (en) Catalytic activated carbon structures and methods of use and manufacture
WO2013043385A3 (en) Catalyst for producing acrylic acids and acrylates comprising vanadium and titanium
JP2012516348A5 (enExample)
MX2015005311A (es) Control de olor efectivo con recubrimientos de moleculas porosas diseñadas.
IN2014MN01551A (enExample)
MY182801A (en) Compound for activating ampk and uses thereof
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
PH12015502516A1 (en) Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment
WO2011106062A3 (en) Silica remediation in water
EP3230266A4 (en) Adsorption of fluorinated anesthetics within the pores of molecular crystals
PH12014000033A1 (en) Absorbent for oral administration, and agent for treating or preventing renal or liver diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)